BACKGROUND: Mycoplasma genitalium (MG) is a sexually transmitted pathogen associated with inflammatory syndromes in men and women. Macrolides and fluoroquinolones are recommended MG treatments. The frequency of MG strains with macrolide resistance-associated mutations (MRMs) and quinolone resistance-associated mutations (qRMs) is increasing worldwide, however these data are sparse in populations in the United States. METHODS: We investigated the prevalence of MG infections with MRMs and qRMs and MG infection concordance within African American couples in Birmingham, AL. We used a real-time polymerase chain reaction to detect MG and identify MRMs. quinolone resistance-associated mutations were detected using traditional polymerase chain reactions amplifying regions in gyrA, gyrB, parC, and parE. The MG concordance in couples was evaluated by MG positivity and MG genotypes. RESULTS: Oral, anal, urine, and/or vaginal specimens were tested from 116 couples. Twenty-eight (12.1%) participants comprising 22 couples tested MG-positive (11.2% in men and 12.9% in women). Macrolide resistance-associated mutations were detected in 17 (60.7%) MG-positive participants, with gender-specific resistance rates of 69.2% for men and 53.3% for women. quinolone resistance-associated mutations were detected in 3 (11.1%) MG-positive participants, all of whom also had MRMs. By MG positivity status, 27.3% of couples were concordant. If MG strain genotypes are also considered, then concordance was 20.0%. CONCLUSIONS: Among heterosexual African Americans with MG infection, about 60% had strains with MRMs and 11% had strains with both MRMs and qRMs, highlighting the potential for MG treatment failure to not only macrolides, but also quinolones. These findings may help to guide clinicians in MG testing and treatment decisions in the United States.
BACKGROUND:Mycoplasma genitalium (MG) is a sexually transmitted pathogen associated with inflammatory syndromes in men and women. Macrolides and fluoroquinolones are recommended MG treatments. The frequency of MG strains with macrolide resistance-associated mutations (MRMs) and quinolone resistance-associated mutations (qRMs) is increasing worldwide, however these data are sparse in populations in the United States. METHODS: We investigated the prevalence of MG infections with MRMs and qRMs and MG infection concordance within African American couples in Birmingham, AL. We used a real-time polymerase chain reaction to detect MG and identify MRMs. quinolone resistance-associated mutations were detected using traditional polymerase chain reactions amplifying regions in gyrA, gyrB, parC, and parE. The MG concordance in couples was evaluated by MG positivity and MG genotypes. RESULTS: Oral, anal, urine, and/or vaginal specimens were tested from 116 couples. Twenty-eight (12.1%) participants comprising 22 couples tested MG-positive (11.2% in men and 12.9% in women). Macrolide resistance-associated mutations were detected in 17 (60.7%) MG-positive participants, with gender-specific resistance rates of 69.2% for men and 53.3% for women. quinolone resistance-associated mutations were detected in 3 (11.1%) MG-positive participants, all of whom also had MRMs. By MG positivity status, 27.3% of couples were concordant. If MG strain genotypes are also considered, then concordance was 20.0%. CONCLUSIONS: Among heterosexual African Americans with MG infection, about 60% had strains with MRMs and 11% had strains with both MRMs and qRMs, highlighting the potential for MG treatment failure to not only macrolides, but also quinolones. These findings may help to guide clinicians in MG testing and treatment decisions in the United States.
Authors: Aneesh K Tosh; Barbara Van Der Pol; J Dennis Fortenberry; James A Williams; Barry P Katz; Byron E Batteiger; Donald P Orr Journal: J Adolesc Health Date: 2007-02-15 Impact factor: 5.012
Authors: Andrew Lau; Catriona S Bradshaw; Dyani Lewis; Christopher K Fairley; Marcus Y Chen; Fabian Y S Kong; Jane S Hocking Journal: Clin Infect Dis Date: 2015-08-03 Impact factor: 9.079
Authors: Jodie Dionne-Odom; William M Geisler; Kristal J Aaron; Ken B Waites; Andrew O Westfall; Barbara Van Der Pol; Li Xiao Journal: Clin Infect Dis Date: 2018-02-10 Impact factor: 9.079
Authors: Laura C Chambers; Jørgen S Jensen; Jennifer L Morgan; M Sylvan Lowens; Sarah S Romano; Patricia A Totten; Olusegun O Soge; James P Hughes; Matthew R Golden; Lisa E Manhart Journal: Sex Transm Dis Date: 2019-12 Impact factor: 2.830
Authors: Arthur H Totten; Gulbu Uzel; Pavel P Khil; Jung-Ho Youn; Jennifer Treat; Craig D Soutar; Steven M Holland; John P Dekker; Christa S Zerbe Journal: Open Forum Infect Dis Date: 2022-09-12 Impact factor: 4.423
Authors: Liteboho D Maduna; Marleen M Kock; Brian M J W van der Veer; Oscar Radebe; James McIntyre; Lieke B van Alphen; Remco P H Peters Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191
Authors: Sally A Harrison; Kristin M Olson; Amy E Ratliff; Li Xiao; Barbara Van Der Pol; Ken B Waites; William M Geisler Journal: Sex Transm Dis Date: 2019-10 Impact factor: 2.830
Authors: Duygu Durukan; Michelle Doyle; Gerald Murray; Kaveesha Bodiyabadu; Lenka Vodstrcil; Eric P F Chow; Jorgen S Jensen; Christopher K Fairley; Ivette Aguirre; Catriona S Bradshaw Journal: Emerg Infect Dis Date: 2020-08 Impact factor: 6.883
Authors: Elizabeth Olson; Kanupriya Gupta; Barbara Van Der Pol; James W Galbraith; William M Geisler Journal: Int J STD AIDS Date: 2021-07-06 Impact factor: 1.359
Authors: James M Daubenspeck; Arthur H Totten; Jason Needham; Monica Feng; Mitchell F Balish; T Prescott Atkinson; Kevin Dybvig Journal: Front Microbiol Date: 2020-10-27 Impact factor: 5.640
Authors: Anne Hammer; Patti E Gravitt; Rachael Adcock; Nicole Patterson; Jack Cuzick; Cosette M Wheeler Journal: Sex Transm Dis Date: 2021-12-01 Impact factor: 2.830